Realcan Pharma initiates share repurchase program

Realcan Pharmaceutical Group (SZSE:002589) announced the initial execution of its previously approved share repurchase plan on February 14, 2025. The company repurchased 4,291,830 shares, representing approximately 0.29% of its total share capital. The buyback occurred through a centralized bidding process via a dedicated securities account, with the highest transaction price at ¥2.99 per share and the lowest at ¥2.93 per share. The total expenditure for the repurchase amounted to ¥12,758,265.4 (excluding transaction costs). This buyback aligns with the previously disclosed repurchase plan, which aims to utilize bank loans and self-owned funds for repurchases between ¥100 million and ¥200 million. The repurchased shares are intended for an employee stock ownership plan. Realcan Pharma will continue to execute the repurchase program based on market conditions and regulatory requirements.